Prognostic value of true castration levels of testosterone in patients with hormone-sensitive prostate cancer
Автор: Gritskevich A.A., Mishugin S.V., Kazantseva M.V., Teplov A.A., Medvedev V.L., Rusakov I.G.
Журнал: Экспериментальная и клиническая урология @ecuro
Рубрика: Онкоурология
Статья в выпуске: 2, 2016 года.
Бесплатный доступ
Prognostic value of true castration levels of testosterone in patients with hormone-sensitive prostate cancer Current guidelines recommend to maintain the target level of testosterone (T) during hormone therapy not higher than 1.73 nmol/l (50 ng/dl). However, in the majority of patients who undergo surgical castration (SC), concentration of T reaches
Androgen deprivation therapy, degarelix, lhrh antagonists, hormone-sensitive prostate cancer, follicle stimulating hormone, testosterone
Короткий адрес: https://sciup.org/142188103
IDR: 142188103
